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Abstract Fever is a common symptom of childhood
infections that in itself does not require treatment. The
UK’s National Institute for Health and Care Excellence
(NICE) advises home-based antipyretic treatment for low-
risk feverish children only if the child appears distressed.
The recommended antipyretics are ibuprofen or paraceta-
mol (acetaminophen). They are equally recommended for
the distressed, feverish child; therefore, healthcare profes-
sionals, parents and caregivers need to decide which of
these agents to administer if the child is distressed. This
narrative literature review examines recent data on ibu-
profen and paracetamol in feverish children to determine
any clinically relevant differences between these agents.
The data suggest that these agents have similar safety
profiles in this setting and in the absence of underlying
health issues, ibuprofen seems to be more effective than
paracetamol at reducing NICE’s treatment criterion, ‘dis-
tress’ (as assessed by discomfort levels, symptom relief,
and general behavior).
Key Points
Clinical data suggest that ibuprofen and paracetamol
have similar safety profiles but underlying health
issues need to be considered when choosing between
the two antipyretics to treat a feverish, distressed
child
Studies suggest that ibuprofen is more effective than
paracetamol at relieving fever-associated discomfort,
providing symptom relief and improving general
behavior
Selecting the most suitable antipyretic for the
individual child may help to optimize the chance of
treatment success first time, thereby limiting the
need to administer further treatment
1 Introduction
Fever is the primary presentation for a host of childhood
illnesses, and its underlying cause is generally benign.
Fever may have a beneficial effect in terms of fighting
infection [1], although its value in the recovery process is
far from clear, since in vivo data are largely lacking. Fever
can, however, be associated with distress and discomfort in
children, leading to a high degree of parental concern. For
febrile children without any indication of a serious under-
lying condition (‘low-risk’ fever), national guidelines rec-
ommend home management [1–4]. However, despite the
recognition over 30 years ago of parental misconceptions
around childhood fever and calls for improved educational
intervention, ‘fever phobia’ remains common, and parents
D. Kanabar (&)
Evelina London Children’s Hospital, St Thomas’ Hospital,
Westminster Bridge Road, London SE1 7EH, UK
e-mail: dkanabar@doctors.org.uk
Drugs R D (2014) 14:45–55
DOI 10.1007/s40268-014-0052-x
and caregivers continue to show uncertainty, misjudgment
and anxiety in managing their feverish child [5–7].
Recently, the UK’s National Institute for Health and
Care Excellence (NICE) issued guidelines for the assess-
ment and initial treatment of the feverish child, an update
of earlier guidelines produced in 2007 [2]. NICE defines
fever as an elevation of body temperature above the normal
daily variation. For the assessment of children with fever,
NICE has developed the ‘traffic light’ system for identi-
fying the risk of a serious illness such as meningitis
(Table 1). Children who have all the green (low-risk)
features and no amber (intermediate-risk) or red (high-risk)
features are most likely to have a self-limiting viral
infection, and can be cared for at home with appropriate
advice provided to parents and caregivers. Key among the
updated recommendations is the advice to treat with an
antipyretic only if the child appears distressed, with a focus
on comforting the child, rather than on achieving normo-
thermia (Table 2). In line with evidence showing increased
discomfort and a lack of efficacy relative to antipyretics [8–
10], physical interventions such as tepid sponging are no
longer recommended for the treatment of fever [2].
Management of the distressed, feverish child therefore
relies on the use of drug intervention and both ibuprofen
and paracetamol (acetaminophen) are given equal status in
the current guidelines. Parents and caregivers therefore
need to choose between the two, the key aspects of which
are compared in Table 3, and may seek guidance from
healthcare professionals (HCPs) as to which is more
appropriate for their child.
Interestingly, despite equal recommendation in guide-
lines, there is evidence to suggest that paracetamol is the
Table 1 NICE guidelines for identifying low-risk, intermediate-risk and high-risk fever in children [2]
Green/low risk Amber/intermediate risk Red/high risk
Color (of skin, lips or
tongue)
Normal color Pallor reported by parent/carer Pale/mottled/ashen/blue
Activity Responds normally to social cues
Content/smiles
Stays awake or awakens quickly
Strong normal cry/not crying
Not responding normally to social
cues
No smile
Wakes only with prolonged
stimulation
Decreased activity
No response to social cues
Appears ill to a healthcare
professional
Does not wake or if roused does not
stay awake





[40 breaths/minute, age [12 months
Oxygen saturation B95% in air
Crackles in the chest
Grunting
Tachypnea: respiratory rate [60
breaths/minute
Moderate or severe chest indrawing
Circulation and
hydration
Normal skin and eyes
Moist mucous membranes
Tachycardia:
[160 beats/minute, age \12 months
[150 beats/minute, age
12–24 months
[140 beats/minute, age 2–5 years
Capillary refill time C3 seconds
Dry mucous membranes
Poor feeding in infants
Reduced urine output
Reduced skin turgor
Other None of the amber or red symptoms
or signs
Age 3–6 months and temperature
C39 C
Fever for C5 days
Rigors
Swelling of a limb or joint
Non-weight bearing limb/not using an
extremity








NICE National Institute for Health and Care Excellence
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‘favored’ antipyretic medication for home management of
pediatric fever [11]. The reasons for this apparent dis-
crepancy are unclear, although over-the-counter (OTC)
paracetamol has been available for longer than ibuprofen,
and brand names such as Calpol and Tylenol are conse-
quently firmly established in the minds of parents. This
familiarity can present advantages (rapid access when
required) and disadvantages (resistance to change). There
may also be perceptions, for both parents and HCPs,
around relative safety and efficacy. This narrative literature
review of recent data aims to determine whether there are
any clinically relevant differences in efficacy and safety
between ibuprofen and paracetamol that may recommend
one agent over the other in the management of the dis-
tressed, feverish child. In addition, it also explores why
there is a discrepancy between current guidelines and the
real-world use of these treatments.
2 To Treat or Not to Treat
Before discussing treatment, it is important to consider
what constitutes ‘distress’ and how parents interpret this
term [12]. Perception of distress is likely to vary markedly
between parents, and may be linked to factors such as level
of education, socioeconomic status and cultural




4 hours 6 hours
Route of OTC
administrationa
Oral, palatable suspension is available Oral, palatable suspension is available
Commercial availability Brands such as Calpol and Tylenol are established
and familiar to parents
Potentially less familiarity with brands such as Nurofen for
Children
Efficacy Effective [2] Effective [2]. Better than paracetamol at reducing fever-




May be preferable for children with gastrointestinal
infection
Risk of gastrointestinal irritation [35], true incidence
uncertain due to under-reporting, short-term use may be
asymptomatic
May be preferable in patients at high risk of
gastrointestinal bleeding
Risk of gastrointestinal bleeding—potentially serious, but
rare. No significant difference in risk from paracetamol [1,
40, 41]
Increased risk of asthma-related outpatient
attendance in children with asthma [49]
May be preferable for children with asthma (but without
aspirin-sensitive asthma)
May be preferable for children with chicken pox Risk of severe cutaneous complications in patients with
varicella or herpes zoster [77]
Risk of hepatotoxicity—potentially serious, but rare
[1, 88]
May be preferable where there is a risk of dosing error or
confusion
May be preferable for children who are dehydrated
or with pre-existing renal disease or multi-organ
failure
Risk of renal toxicity—potentially serious, but rare [1]
a Different routes of administration may be used for pediatric fever in hospitalized patients
Table 2 NICE guidelines for antipyretic interventions in children [2]
Antipyretic agents do not prevent febrile convulsions and should not be used specifically for this purpose
Tepid sponging is not recommended for the treatment of fever
Children with fever should not be underdressed or over-wrapped
Consider using either paracetamol or ibuprofen in children with fever who appear distressed
Do not use antipyretic agents with the sole aim of reducing body temperature in children with fever
When using paracetamol or ibuprofen in children with fever:
Continue only as long as the child appears distressed
Consider changing to the other agent if the child’s distress is not alleviated
Do not give both agents simultaneously
Only consider alternating these agents if the distress persists or recurs before the next dose is due
NICE National Institute for Health and Care Excellence
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background [13–15]. This may impact on when a parent
decides to start treating their child with an antipyretic,
whether to change antipyretics, or indeed when to consult
an HCP. The problem of defining distress is recognized in
the NICE guidelines, and the Guideline Development
Group has called for studies on home-based antipyretic use
and parental perception of distress caused by fever in order
to clarify issues such as triggers for antipyretic use and
help-seeking behavior [2].
The rationale for treating only the distressed, feverish
child is based on the fact that absolute body temperature
alone does not appear to be an indicator of serious infection
[16, 17]. In addition, there is no evidence that fever in itself
increases the risk of parentally-feared adverse events such
as febrile convulsions or brain damage [18], and lowering
temperature with antipyretics does not appear to be effec-
tive at preventing febrile convulsions [19, 20]. Based on
such data, recent guidelines emphasize the need to treat
only the symptoms of fever in children who are either in
discomfort or distressed, and not to focus on normothermia
[1–3]. Despite this, an elevated body temperature (what-
ever site or method of measurement is used), even below
38 C, continues to be a cause of concern for many parents
[7]. Unfounded concerns contribute to reports that the vast
majority of caregivers would give antipyretic medication to
a feverish child, even if the child appeared otherwise
comfortable [7, 13, 21]. Overall, it seems that parental
misconceptions around fever and ‘fever phobia’ have
changed little since this problem was first recognized over
30 years ago [6]. Overcoming such concerns and gaining
parental acceptance of current recommendations not to
give antipyretics simply to reduce fever in children, but
only to alleviate distress [2, 22], is clearly a major
challenge.
3 Treating the Distressed, Feverish Child
While reduction of fever should not be the primary indi-
cation for antipyretic treatment according to NICE guide-
lines, when a child is distressed, treatment with antipyretics
is likely to ease symptoms. The distress experienced by
feverish children may in fact be due to the mismatch in
body and environmental temperatures, as well as any ill-
ness-associated pain. It is clear to see why alleviating these
symptoms could reduce the distress associated with fever.
3.1 Fever Reduction
Despite recommendations to treat distress rather than fever,
‘fever phobia’ means that fever itself is currently the target
of therapy for many parents, with a rapid and prolonged
effect being their likely priority for comforting their child
and to minimize medication. Overall, meta-analyses sug-
gest that ibuprofen provides more rapid and longer lasting
fever reduction in children compared with paracetamol
[23–25]. In a large, randomized, blinded study of para-
cetamol plus ibuprofen for the treatment of fever in chil-
dren (PITCH), involving 156 children who were being
managed at home, ibuprofen was shown to provide faster
fever clearance and longer time without fever in the first
24 hours compared with paracetamol [26].
3.2 Symptomatic Relief
Given that the NICE guidelines do not recommend the use
of antipyretic treatment solely to reduce temperature, the
primary consideration in antipyretic choice should be relief
of distress (i.e., the recommended indications for antipy-
retic use in childhood fever). Subjective assessments such
as how uncomfortable or distressed a child appears are
clearly less easy to quantify than temperature reduction;
nevertheless, they have been assessed in a number of
studies. The PITCH study found that treatment with ibu-
profen led to a greater number of children being recorded
as having no discomfort at 24 hours (69 % vs 44 % for
paracetamol) (Fig. 1) [26]. Based on such findings, the
authors of the PITCH study recommended that ibuprofen
should be used as first-line therapy in feverish children [11,
26].
The findings of the PITCH study are in line with an
earlier study which also reported that comfort (assessed on
scores of general behavior and degree of relief) was higher
with ibuprofen compared with paracetamol [27]. Interest-
ingly, in a study by Autret-Leca and colleagues [28], sig-
nificantly more parents of children treated with ibuprofen
rated the drug as ‘very efficacious’ compared with parents
of children treated with paracetamol, despite the fact that
there was no measurable difference in antipyretic efficacy
(area under the temperature reduction curve expressed as
an absolute difference from baseline, from 0 to 6 h)
Fig. 1 Percentage of children without fever-associated symptoms at
24 hours (the PITCH study) [26]
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between ibuprofen and paracetamol. This suggests that the
superiority of ibuprofen in terms of symptom relief may be
related to additional benefits other than simply temperature
reduction. For example, ibuprofen has been shown to be
more effective than paracetamol for pediatric pain relief in
several studies in different settings [29–31] and in a recent
meta-analysis [25], suggesting that pain may be an
important contributory factor to a child’s overall discom-
fort when suffering from the effects of a febrile illness.
3.3 Efficacy: Summary
Based on available data, ibuprofen appears to have a more
rapid onset and longer duration of effect, and provides
more effective relief of fever-associated discomfort com-
pared with paracetamol, particularly in the first 24 hours of
the child’s illness. Rapid relief of symptoms is clearly an
important consideration in feverish children; a child who is
comfortable is more likely to maintain nutrition and
hydration, for example. In addition, the longer duration of
action of ibuprofen may also improve sleep patterns [32].
Taken together, rapid and prolonged symptomatic relief not
only has benefits for the child, but also for the wider
family.
3.4 Safety
Safety is clearly a primary consideration in the choice of
antipyretic. Overall, ibuprofen and paracetamol are con-
sidered to have similar safety and tolerability profiles in
pediatric fever, and this has been confirmed in meta-anal-
yses [25, 33]. For example, a recent meta-analysis
including 19 evaluable studies found no significant differ-
ence between the two agents in terms of the incidence of
adverse events in pediatric patients (odds ratio [OR] 0.82;
95 % confidence interval [CI] 0.60–1.12) [25]. Larger
studies are, however, required to adequately detect and
quantify rare adverse effects.
Ibuprofen and paracetamol are considered to be gener-
ally well tolerated by children [34]; however, a number of
specific safety issues are often raised for both agents which
may impact on recommendations and prescribing practice.
The question arises as to whether these concerns are evi-
dence-based, or have arisen due to medical ‘myths’ or
‘dogma’.
3.4.1 Gastrointestinal Effects
Concerns regarding potential adverse gastrointestinal (GI)
effects with the use of non-steroidal anti-inflammatory
drugs (NSAIDs) are relatively common. While GI bleeding
is the most serious, GI irritation may be a more frequent
adverse event [35], although its true incidence is uncertain
since many mild cases are likely to go unreported. In a
double-blind study of children taking ibuprofen (n = 76)
or paracetamol (n = 74) for up to 3 days, there was only
one GI event (diarrhea) reported as possibly related to
treatment, and this occurred in the ibuprofen group [36].
Potentially, GI irritation could be important in the setting
of a GI infection since there is synergism for the devel-
opment of peptic ulcers and ulcer bleeding between Heli-
cobacter pylori infection and NSAID use [37]. However, as
discussed below, clinical data suggest that—for short-term
use such as pediatric fever-related symptoms, and with
doses available OTC—the risk of GI events is no greater
for NSAIDs than for paracetamol.
Dose-dependent GI toxicity (e.g., bleeding) in associa-
tion with NSAID treatment in adults is well documented in
‘at-risk’ patients [38]. However, at OTC doses in adults,
symptomatic GI side effects with ibuprofen are comparable
with placebo and treatment is well tolerated [38].
Whilst there are less data regarding GI effects in
febrile children, in one of the largest trials comparing
ibuprofen and paracetamol use, the risk of GI bleeding
was low (7.2 per 100,000 for ibuprofen and 0 per
100,000 for paracetamol), with no statistically significant
difference between the two treatment groups (p = 0.31)
[39]. The four cases of GI bleeding reported in this study
occurred in children treated with ibuprofen, all of whom
were managed conservatively with no endoscopy being
required [39]. This finding is occasionally cited as a
potential cause for concern, despite the lack of signifi-
cance relative to paracetamol. However, since this early
study, other studies have confirmed that upper GI com-
plications (UGICs) are rare events in children treated
with NSAIDs, with a low absolute risk [40, 41]. In
addition, a recent case-controlled study in children
admitted to hospital via emergency departments for acute
conditions over an 11-year period found no significant
difference in risk of UGICs with paracetamol (adjusted
OR 2.0; 95 % CI 1.5–2.6) compared with ibuprofen
(adjusted OR 3.7; 95 % CI 2.3–5.9) [41].
One result of the perceived association of NSAIDs and
UGICs is the common advice to take ibuprofen with food
(or fluids such as milk), the rationale being that such co-
administration exerts a ‘protective’ effect in the GI tract.
Respectively, food and fluids also guard against glutathione
depletion (and the attendant risk for hepatic toxicity) [42]
and dehydration (and the attendant risk for renal toxicity)
[43]. This has a particular impact for OTC use in childhood
fever, where children may feel too unwell to eat or drink.
As discussed in a recent literature review, the effect of
fasting on NSAID-related GI effects has never been
properly studied in humans [44]. Food is known to delay
the achievement of peak levels of NSAIDs and so impacts
on efficacy. Therefore, the authors suggested that it may be
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more appropriate to advocate OTC ibuprofen be taken on a
fasting stomach in order to achieve a rapid onset of action
and effect, thereby avoiding the use of an ‘extra’ dose [44].
3.4.2 Asthma
Aspirin-induced asthma is a well recognized clinical syn-
drome, arising most commonly in adults, and infrequently
in children [45], and thought to be related to COX inhi-
bition, which shows a high level of cross-sensitivity with
other NSAIDs [46, 47]. A randomized, double-blind, pla-
cebo-controlled study found that ibuprofen-induced bron-
chospasm occurred in 2 % of pediatric patients with
asthma with a further 2 % demonstrating a clinical
decrease in spirometric measurements [48].
Ibuprofen does not appear to exacerbate asthma in
children without a history of aspirin sensitivity, and may in
fact be associated with a lower risk of exacerbation than
paracetamol [47]. In two large studies of febrile children
[36, 49], the unexpected finding was a slightly reduced risk
of asthma compared with paracetamol usage. In one of
these studies, a randomized controlled trial in febrile
children with asthma, those who received ibuprofen were
significantly less likely to require outpatient visits for
asthma (3.0 % for ibuprofen vs 5.1 % for paracetamol;
relative risk 0.56, 95 % CI 0.34–0.95) compared with
children who received paracetamol [49]. Paracetamol use
during pregnancy has been implicated in asthma develop-
ment and the increasing incidence of asthma in adults and
children in epidemiologic, observational and pathophysio-
logic studies (reviewed in [50–52] and more recently in a
prospective birth cohort study [53]). Given the widespread
use of paracetamol in children, there has been a call for
causation to be proved or disproved in adequately powered
placebo-controlled trials [54], and clearly more research is
required in this field.
3.4.3 Renal Effects
NSAIDs have been associated with the development of
acute kidney injury (AKI), which is thought to be related to
a reduction in prostaglandin synthesis [55], which is
required for renal perfusion in dehydration [56]. This is a
potentially serious, albeit rare, adverse effect associated
with NSAID use. There were no incidences of acute renal
failure in a large practitioner-based population study which
included 55,785 children treated with ibuprofen [39], or in
the Boston Collaborative Fever study which included
27,065 febrile children randomized to ibuprofen [57]. A
further study by the same authors found that, with short-
term use of ibuprofen, the risk of less severe renal
impairment is small and not significantly greater than with
paracetamol [58].
Similarly, a large-scale pediatric study by Ashraf and
colleagues [59] found no incidences of renal conditions in
over 30,000 children treated with either ibuprofen or par-
acetamol. There have, however, been rare case reports of
reversible renal insufficiency in children with febrile illness
treated with ibuprofen or other NSAIDs, largely associated
with volume depletion [60–62]. Dehydration is common in
children with fever [63] and is an important risk factor for
NSAID-induced acute renal failure; this has led some
experts to recommend caution with ibuprofen use in chil-
dren with dehydration or pre-existing renal disease [1, 22].
Recently, a retrospective chart review of 1,015 children
with AKI managed over an 11.5-year period concluded that
27 cases (2.7 %) were associated with NSAID use (pre-
dominantly ibuprofen), and that younger children
(\5 years of age) were more likely to require dialysis or
admission into intensive care units [64]. This retrospective
study raises obvious concerns; however, it has a number of
limitations. Most importantly, patients with a history of
volume depletion, an independent risk factor for AKI, were
not excluded from the analysis. The most common pre-
senting symptoms in this study were vomiting and
decreased urine output, and the majority of children defined
as having NSAID-associated AKI had a history of volume
depletion. One possibility is that these dehydrated patients
may have developed AKI independently of NSAID use.
In clinical practice, the author’s experience is that renal
problems arising out of short-term usage of ibuprofen in
feverish children are an unlikely occurrence; nevertheless,
caution (and common sense) should be applied when
administering any agent that may interfere with renal
function in a child with volume depletion and/or multi-
organ failure.
3.4.4 Hepatotoxicity and Risk of Overdose
Overdose of either drug can cause hepatotoxicity (which
can be asymptomatic), although this is most often a risk
linked with paracetamol. Hepatotoxicity is a potentially
serious, albeit rare, adverse effect that has been reported
with paracetamol in children at recommended doses [65–
67] as well as in the setting of an acute overdose [68, 69].
There is also the possibility of paracetamol-related hepa-
titis due to chronic overdose following either the admin-
istration of supratherapeutic doses or too frequent
administration of appropriate single doses [1, 70]. Current
UK dosing guidelines are age-based (Table 4). However, a
recent UK study found that underweight children are at risk
of receiving approximately 200 %, and average-weight
children up to 133 % of the recommended single and
cumulative daily dose of paracetamol, leading to recently
proposed changes in dosing recommendations [71, 72]. To
reduce the risk of overdosing or underdosing, dosing
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guidelines in some other countries are based on weight or
both age and weight; the typical recommendation for ibu-
profen is 5–10 mg/kg per dose, while for paracetamol it is
10–15 mg/kg per dose [1, 22, 73].
Reports of complications following ibuprofen overdose,
particularly in children, are rare. The vast majority of
individuals who overdose on ibuprofen alone have no, or
only mild, symptoms [74]. Fatal overdose in adults is
extremely rare and is generally related to complicating
factors such as the presence of other drugs. Cases of
symptomatic overdose in children have been reported fol-
lowing ingestion of over 440 mg/kg [75], but in general the
risk of serious complications following ibuprofen overdose
is low [76].
3.4.5 Other
An increased risk of severe cutaneous complications in
patients with varicella or herpes zoster has been reported
for NSAIDs but not for paracetamol [77]. Consequently, it
has been recommended that fever and pain associated with
varicella or herpes zoster infection should be treated with
paracetamol, not an NSAID [77].
3.4.6 Safety: Summary
Specific safety issues that are often cited for ibuprofen and
paracetamol may be a consideration for specific patient
populations, but for the average child with symptoms of
distress related to low-risk fever (that is, in the absence of
underlying health issues) they are of less concern.
Ibuprofen and paracetamol have similar safety and tolera-
bility profiles when short-term OTC doses are used.
3.5 Combination Therapy
The use of combination therapy with either alternating or
simultaneous use of ibuprofen and paracetamol in feverish
children is controversial. In children, clinical trials have
reported that alternating ibuprofen and paracetamol is more
effective at reducing fever than either agent alone [11, 78,
79], but there are few data on fever-related symptoms or
distress. Recent systematic reviews have concluded that
there is little evidence of any significant benefit (or harm)
from combined or alternating treatment compared with the
use of either drug alone [80, 81] and, in their recent update,
NICE concluded that there was little evidence in the
community that alternating therapy improves distress.
Alternating the two agents is therefore only recommended
if both have been ineffective as standalone treatments [2],
the proviso being how a parent defines ‘ineffective’. Fac-
tors such as parental anxiety, poorly obtained or recorded
temperatures, subjective assessment of level of discomfort
or distress, and a lack of knowledge on the time to onset of
antipyretic effect may contribute both to dosing more fre-
quently than recommended and to a perceived lack of
response to monotherapy, resulting in unnecessary (and
potentially harmful) use of alternating therapy [15]. A
further consideration regarding alternating treatment is the
possibility of parental confusion, which may result in
accidental overdose or underdosing [15, 82, 83]. While the
recommended dosing interval for ibuprofen is 6 hours, it is
Table 4 Standard over-the-counter (OTC) dose for paracetamol and ibuprofen
Paracetamol Ibuprofen
Age 2–3 months: 60 mg, with a further 60 mg after 4–6 hours if
necessary (maximum of two doses) [89]
Age 3–5 months: 50 mg three times a day (maximum of three doses in
24 hours, do not use for more than 24 hours)
Age 3–6 months: 60 mg every 4–6 hours (maximum of four doses
in 24 hours)
Age 6 months to 1 year: 50 mg three to four times a day
Age 6–24 months: 120 mg every 4–6 hours (maximum of four
doses in 24 hours)
Age 1–4 years: 100 mg three times a day
Age 2–4 years: 180 mg every 4–6 hours (maximum of four doses
in 24 hours)
Age 4–7 years: 150 mg three times a day
Age 4–6 years: 240 mg every 4–6 hours (maximum of four doses
in 24 hours)
Age 7–10 years: 200 mg three times a day
Age 6–8 years: 250 mg every 4–6 hours (maximum of four doses
in 24 hours)
Age 10–12 years: 300 mg three times a day
Age 8–10 years: 375 mg every 4–6 hours (maximum of four doses
in 24 hours)
Age 12–16 years: 200 to 400 mg three to four times a day
Age 10–16 years: 500 mg every 4–6 hours (maximum of four
doses in 24 hours)
Source: [90]
Source: [90]
Higher doses and different routes of administration may be used for pediatric fever in hospitalized patients
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4 hours for paracetamol, therefore a simple alternating
dosing regimen can be difficult.
It is possible that treatment with a single combined dose
of ibuprofen and paracetamol may offer a more effective
option, with a reduced risk of dosing confusion compared
with alternating therapy. There is a theoretical benefit to the
co-administration of two antipyretics with different modes
of action. Data in adults suggest that co-administration of
ibuprofen and paracetamol provides highly effective pain
relief [84] and antipyretic efficacy [85] (although distress
was not measured in these patients), with a similar safety
profile to each agent alone [86]. However, efficacy and
safety data for combination therapy in children are lacking
and, therefore, currently the author’s recommendation
would be that this practice is not suggested for general OTC
usage, in agreement with the latest NICE recommendations.
4 Summary and Conclusions
The NICE guidelines give equal recommendation to the
use of paracetamol or ibuprofen for the short-term treat-
ment of distress in low-risk feverish children [2]. There-
fore, the caregiver or HCP has to make a choice between
these readily available OTC agents.
The aim of this review has been to compile and compare
the efficacy and safety data from available clinical studies
that directly compare ibuprofen and paracetamol such that
any clinically relevant differences can be considered and
sensible conclusions drawn as to whether one agent has
advantage over the other, and to enable the caregiver (or
HCP) to make an informed choice.
The age of the child can be a factor in the decision of
which antipyretic to use, since paracetamol can be given at
2 months of age whereas ibuprofen has an OTC license in
infants aged over 3 months (weight [ 5 kg) with a higher
threshold of 6 months in some other countries, including
the USA. However, from the age of 3 (or 6) months, both
paracetamol and ibuprofen are suitable (Table 4).
Antipyretic efficacy data for ibuprofen and paracetamol
are not relevant to the use of these agents in feverish
children, considering the NICE guidance to focus on
comforting the child, rather than on achieving normother-
mia. However, they do provide useful information. Anti-
pyretic efficacy may indicate relevant pharmacologic onset
and duration of effect, especially where distress is due to
the mismatch in environmental and body temperatures.
However, distress is likely multi-factorial so antipyretic
efficacy cannot currently be used as a direct surrogate for
efficacy against distress in feverish children; further
research is required.
The evidence indicates that ibuprofen may provide
greater relief of symptoms in the distressed, feverish child
compared with paracetamol [26, 27]. The longer duration
of action of ibuprofen means the number of doses can be
kept to a minimum, and a single dose may be all that is
required in certain circumstances (e.g., post-immunization
pyrexia). In addition, the faster onset of action and greater
symptomatic relief with ibuprofen means that the NICE
recommendation to relieve distress can be achieved more
rapidly, with the concomitant advantage of a faster return
to ‘normal’ family life.
Meta-analyses confirm that the safety and tolerability
profiles of paracetamol and ibuprofen in pediatric fever are
similar [25, 33]. Both drugs are associated with specific
rare adverse effects, which are difficult to detect and
quantify in all but the largest clinical trials, and which may
be relevant to specific patient populations. For example,
ibuprofen may be preferable in the setting of asthma
(without known aspirin sensitivity) or where there is a risk
of the parent or caregiver experiencing confusion over-
dosing (and potentially overdosing the child), whilst par-
acetamol may be preferable when children have chicken
pox, are dehydrated, have pre-existing renal disease or
multi-organ failure, or are at increased risk of GI bleeding
(Table 3). In reality, such children are likely to be under
the care of a clinician, who is best placed to weigh up the
risks and benefits of each drug for the individual patient.
Paracetamol is generally conceived by the public (or
HCPs) as being a ‘safer agent’ with fewer adverse effects.
Possible reasons to explain this misconception could
include the earlier potential exposure to paracetamol (after
the child’s first immunization at 2 months of age), perhaps
leading to a general misconception around its safety and
tolerability. Therefore, with earlier familiarity, in the
absence of advice to the contrary, many parents are likely
to remain loyal to a drug they are used to. In addition, the
fact that paracetamol is licensed for use in younger children
may mean that parents perceive it to be a ‘safer’ medica-
tion. Familiarity also introduces risks, and the conse-
quences of too frequent and unnecessary use of
paracetamol can be serious. A further reason may be the
often-cited advice to give ibuprofen with food (or milk),
which could be associated with a perception of GI intol-
erability, despite the lack of evidence relating to short-term
OTC usage.
While alternating treatment with ibuprofen and para-
cetamol may offer some advantages over monotherapy, a
lack of efficacy and safety data in children, together with
concerns around dosing confusion and risk of overdose, are
currently considered to outweigh any benefit except in
patients where single-agent treatment is ineffective.
The NICE guidelines recommend that children should
only be treated for as long as symptoms persist; avoiding
overtreatment is an important consideration with antipy-
retics, as with any drug. Conversely, delaying treatment or
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underdosing may result in unnecessary discomfort to a
distressed, feverish child, and may affect their desire to eat
or drink. Ongoing distress in febrile children may also
impact parents and the wider family. Fears that antipyretic
use may prolong febrile illness have been shown to be
unfounded and there is there is little evidence to suggest
that antipyretics mask the symptoms and signs of serious
illness [87]. Encouraging the appropriate use of antipyret-
ics in distressed, feverish children is therefore clearly
important.
In conclusion, fever is a common symptom of childhood
infection which in itself does not require treatment. How-
ever, fever in children can be distressing for all concerned
and there is a need for improved education and healthcare
advice so that parents and caregivers can confidently and
effectively manage a child’s low-grade fever at home. This
includes being aware of the choice of OTC antipyretics
available to them, knowing when to treat with an antipy-
retic agent, and being well informed on which agent to
choose. The long-term goal of childhood fever manage-
ment is improved self-care/home-care plans, with the
advice and help of local pharmacists. This approach will
help to empower parents and caregivers, enabling them to
make informed decisions about their child’s wellbeing
rather than relying on general practitioners or emergency
departments. NICE guidelines recommend treatment when
dealing with a distressed, feverish child, with the focus on
comforting the child rather than reducing the temperature.
Whilst the guidelines do not recommend one agent over
another, evidence presented in this paper suggests that
ibuprofen may provide greater efficacy in terms of the
relief of symptoms in the distressed, feverish child and that
short-term OTC ibuprofen and paracetamol have similar
safety and tolerability profiles, although each may be pre-
ferred in some specific patient populations.
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